RBC
DCPH

Romano Brothers & Co’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Romano Brothers & Co’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15
Closed -$246 – 1022
2022
Q4 		$246 Buy
+15
New +$244 ﹤0.01% 1037

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Romano Brothers & Co's DCPH Position: Q1 2023 in Review

Romano Brothers & Co sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2023, closing a stake of 15 shares — an estimated $246 sold.

Romano Brothers & Co first reported a position in DCPH in Q4 2022 and held it in 1 quarter. The position peaked at $246 in Q4 2022. 146 funds tracked by Wall St. Rank hold DCPH as of Q1 2023.

  • Romano Brothers & Co reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 15 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $246.
  • Romano Brothers & Co first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $246 in Q4 2022.
  • 146 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.